Expert Review in Relapsed/Refractory Chronic Lymphocytic Leukemia

Expert Review in Relapsed/Refractory Chronic Lymphocytic Leukemia

View Activity

Activity Features

Downloadable Slides

Expert Discussion

Opinion Poll

Activity Overview

Gain expert insight into treatment options for relapsed/refractory chronic lymphocytic leukemia (R/R CLL). View leading investigators discussing the standard of care for R/R CLL and how new trial data might impact the treatment paradigm.


  • Barbara Eichhorst, MD, PhDUniversity Hospital Cologne
    Cologne, Germany
  • John Gribben, MD, DSc, FRCP, FRCPath, FMedSciBarts Cancer Institute
    London, United Kingdom
  • John Seymour, MBBS, PhD, FRACPPeter MacCallum Cancer Centre
    Melbourne, Australia


  • Standard of care for relapsed/refractory CLL
  • Combination therapy for CLL
  • Second-generation targeted agents in CLL

Target Audience

This educational activity is intended for hematologists, oncologists, and other healthcare professionals involved in management of CLL.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify features that can inform treatment decision making, such as persistence of minimal residual disease and the presence of deleterious cytogenetic aberrations
  • Assess recent efficacy and safety results from investigations into novel treatment strategies for R/R CLL
  • Select optimal treatment for patients with R/R CLL based on current best practices and recent trial data
View Activity

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.


This activity is provided by prIME Oncology.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.



This educational activity is supported by a grant from AbbVie.

Activity Date

December 21, 2017

December 21, 2018